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Randomized clinical trials have conclusively shown that
beta-blocker therapy reduces mortality by about 20%
during the 2-year period following myocardial infarction
(MI) (1–3). On the basis of these data, international
guidelines recommend beta-blocker therapy as a class 1
recommendation for patients who have MI, including
ST-segment elevation myocardial infarction (STEMI),
initiated within the ﬁrst 24 h and continued after hospitali-
zation if there is no contraindication (4).See page 592Most of the evidence for beneﬁt of beta-blockers
following acute MI predates the era of reperfusion, and
in particular, primary percutaneous coronary intervention
(PCI). Given that PCI results in less residual myocardial
damage and lower mortality, it is possible that the beneﬁts
of beta-blocker therapy, which are thought to be due to a
decrease in myocardial oxygen demand in regions down-
stream of stenoses by decreasing heart rate and inotropy,
may be less following primary PCI. Thus it is an important
question to understand whether beta-blocker therapy
following primary PCI offers a beneﬁt to these patients (5).*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardiovascular
Interventions or the American College of Cardiology.
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funding from Medtronic Foundation.Few randomized trials are available that address the
effects of beta-blockers following reperfusion therapy. The
COMMIT (Clopidogrel and Metoprolol in Myocardial
Infarction Trial) examined the effect of early intravenous
then oral metoprolol in 45,852 patients with STEMI and
found no difference in mortality at 30 days. The trial did
ﬁnd that beta-blockers resulted in less reinfarction and
ventricular ﬁbrillation at the expense of more cardiogenic
shock, which is consistent with the beneﬁt of this therapy
in hemodynamically stable patients (who are not suscepti-
ble to shock) (6). A more recent, small trial, the Effect of
Metoprolol in Cardioprotection During an Acute
Myocardial Infarction Trial, showed patients with primary
PCI had reduced infarct size and improved left ventricular
function with no excess of adverse events during the ﬁrst 24
h with intravenous metoprolol (7).
Observational studies have also addressed the effects of
beta-blockers following primary PCI. The CADILLAC
(Controlled Abciximab and Device Investigation to Low
Late Angioplasty Complications) trial looked at 2,082 pa-
tients to address the association of intravenous beta-blocker
therapy before primary PCI and outcome. They found lower
30-day mortality (1.5% vs. 2.8%, p ¼ 0.03) and improved
left ventricular ejection fraction from baseline to 7 months
(3.8% vs. 1.3%, p ¼ 0.01) (8).
When considering the beneﬁt of oral beta-blocker
therapy after primary PCI for patients with STEMI, even
fewer data are available. A retrospective review of obser-
vational data from 4 of the PAMI (Primary Angioplasty in
Myocardial Infarction) studies, including 2,442 patients,
found lower 6-month mortality associated with oral beta-
blocker therapy at discharge (2.2% vs. 6.6%, p > 0.0001;
odds ratio [OR]: 0.43, p ¼ 0.0016) (9). This study also
showed that the associated lower mortality was conﬁned
to high-risk subgroups deﬁned as those with an ejection
fraction (EF) <50% (OR: 0.34, p > 0.0001) and those
with multivessel coronary disease (OR: 0.26, p < 0.001). In
a prospective observational study, OACIS (Osaka Acute
Coronary Insufﬁciency Study), which included 5,628 pa-
tients with median follow-up of 1,430 days, the reduction
in mortality associated with oral beta-blocker therapy was
also seen in high-risk patients (hazard ratio [HR]: 0.60,
95% conﬁdence interval [CI]: 0.42 to 0.85, p ¼ 0.005) or
those who received diuretic agents (HR: 0.60, 95% CI:
0.40 to 0.91, p ¼ 0.016) (10). For low-risk patients with a
preserved EF who had STEMI treated with PCI, registry
data from Japan including 12,824 patients with an EF
>40% did not show a difference in 3-year mortality
associated with oral beta-blocker therapy at hospital
discharge (11). Thus, most but not all observational data
have suggested a beneﬁt, varying with risk, with oral beta-
blockers.
The question about the beneﬁts of beta-blocker therapy
might be similarly asked of angiotensin-converting enzyme
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603(ACE) inhibitors or angiotensin-receptor blockers after pri-
mary PCI. It seems prudent to extrapolate that for patients
with heart failure and/or left ventricular dysfunction, and
probably for all patients with signiﬁcant anterior MI, ACE
inhibitors are equally important with or without primary
PCI. It is also notable that in the overall effect of ACE
inhibitors on mortality over the ﬁrst 4 to 6 weeks after acute
MI, 40% of the survival beneﬁt occurred in the ﬁrst day
(12). Thus early initiation of ACE inhibitors following a
large MI (in the absence of hypotension) may be as or more
important than early initiation of beta-blockers.
The results in this issue by Yang et al. (13) are from a
high-quality, large registry of 8,510 patients with STEMI
treated with primary PCI and focus on outcomes associated
with oral beta-blocker therapy. Consistent with previous
studies, beta-blocker therapy at discharge was associated
with lower mortality during a median follow-up of 1-year
(HR: 0.52, 95% CI: 0.38 to 0.70, p < 0.001). Interestingly,
the subgroup analysis of this study showed a consistent as-
sociation with lower mortality among low-risk patients
deﬁned as those with a preserved EF and single-vessel
coronary disease.
These ﬁndings are supportive of the conclusion that oral
beta-blocker therapy at discharge in patients treated with
primary PCI results in better outcomes. The 50% lower
mortality in this study is substantially more than the 20%
estimate from randomized trials and therefore raises some
question regarding the degree of beneﬁt seen in this study.
As with all observational data, inference of treatment effect
in this study is hazardous. This and related studies have
selection bias for the use of beta-blockers that is related
to measured and unmeasured factors. Whereas propensity
scoring can control confounding, it cannot account for un-
measured confounders. As an example, propensity scoring
was used in observational studies to evaluate whether right
heart catheterization is beneﬁcial to guide therapy in criti-
cally ill patients. Propensity score adjustment found that
right heart catheterization was associated with higher mor-
tality. A subsequent randomized clinical trial, the ESCAPE
(Evaluation Study of Congestive Heart Failure and Pul-
monary Artery Catheterization Effectiveness) trial (14)
found no effect on overall total mortality. This provides an
example of propensity scoring not being reliable to adjust for
confounders in order to estimate treatment effect that leaves
the randomized comparison as a “gold standard.”
Another limitation of this study (and other related
observational studies) is that beta-blocker therapy was
deﬁned as having a beta-blocker prescribed at the time of
discharge, with little information about whether and how
beta-blockers were continued. Despite these limitations,
however, this observational study provides some evidence
that the well-established beneﬁts of beta-blockers are likelyconsistent for patients treated with primary PCI, including
patients at lower risk.
Reprint requests and correspondence: Dr. Meena Rao, Cardi-
ology Division, Duke Clinical Research Institute, 2301 Erwin
Road, DUMC 3845, Durham, North Carolina 27710. E-mail:
meena.rao@duke.edu.
REFERENCES
1. Timolol-induced reduction in mortality and re-infarction in patients
surviving acute myocardial infarction. N Engl J Med 1981;304:801–7.
2. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol
trial: effects on mortality and morbidity in acute myocardial infarction.
Circulation 1983;67:126–32.
3. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockage during
and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis 1985;27:335–71.
4. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction a
report of the American College of Cardiology Foundation/American
Heart association Task Force on Practice Guidelines. J Am Coll Cardiol
2013;61:e78–140.
5. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial
infarction: experimental observations and clinical implications. Circu-
lation 1990;81:1161–72.
6. Chen ZM, Pan HC, Chen YP, et al., for the COMMIT Collaborative
Group. Early intravenous then oral metoprolol in 45,852 patients with
acute myocardial infarction: randomised placebo-controlled trial. Lancet
2005;366:1622–32.
7. Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-
blockade before primary angioplasty on survival in patients undergoing
mechanical reperfusion therapy for acute myocardial infarction. J Am
Coll Cardiol 2004;43:1780–7.
8. Ibanez B, Mayaca C, Sánchez-Brunete V, et al. Effect of early meto-
prolol on infarct size in ST-segment elevation myocardial infarction
patients undergoing primary percutaneous coronary intervention: the
Effect of Metoprolol in Cardioprotection During an Acute Myocardial
Infarction. Circ 2013;128:1495–503.
9. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy
improve clinical outcomes of acute myocardial infarction after success-
ful primary angioplasty? J Am Coll Cardiol 2004;43:1773–9.
10. Nakatani D, Sakata Y, Suna S, et al., for the OACIS Investigators.
Impact of beta blockade therapy on long-term mortality after ST-
segment elevation acute myocardial infarction in the percutaneous
coronary intervention era. Am J Cardiol 2013;111:457–64.
11. Ozasa N, Kimura T, Morimoto T, et al., for the j-Cypher Registry
Investigators. Lack of effect of oral beta blocker therapy at discharge on
long-term clinical outcomes of ST-segment elevation acute myocardial
infarction after primary percutaneous coronary intervention. Am J
Cardiol 2010;106:1225–33.
12. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications
for ACE inhibitors in the early treatment of acute myocardial infarction:
systematic overview of individual data from 100,000 patients in ran-
domized trials. Circulation 1998;97:2202–12.
13. Yang JH, Hahn J-Y, Song YB, et al. Association of beta-blocker therapy
at discharge with clinical outcomes in patients with ST-segment
elevation myocardial infarction undergoing primary percutaneous cor-
onary intervention. J Am Coll Cardiol Intv 2014;7:592–601.
14. The ESCAPE Investigators and ESCAPE Study Coordinators. Eval-
uation study of congestive heart failure and pulmonary artery catheter-
ization effectiveness: the ESCAPE trial. JAMA 2005;294:1625–33.
Key Words: beta-blocker therapy - myocardial infarction -
percutaneous intervention - ST-segment elevation.
